Leap Therapeutics (LPTX) to Release Quarterly Earnings on Wednesday

Leap Therapeutics (NASDAQ:LPTX) is projected to announce its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 20, 2025 at 9:30 AM ET.

Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). On average, analysts expect Leap Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Leap Therapeutics Stock Performance

Leap Therapeutics stock opened at $0.46 on Monday. Leap Therapeutics has a 52 week low of $0.22 and a 52 week high of $3.61. The firm has a market capitalization of $18.99 million, a PE ratio of -0.29 and a beta of -0.06. The business’s 50-day simple moving average is $0.44 and its 200-day simple moving average is $0.38.

Institutional Trading of Leap Therapeutics

An institutional investor recently raised its position in Leap Therapeutics stock. Acadian Asset Management LLC raised its holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 470.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,280,531 shares of the company’s stock after buying an additional 1,056,047 shares during the period. Acadian Asset Management LLC owned 3.09% of Leap Therapeutics worth $389,000 at the end of the most recent reporting period. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Leap Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut Leap Therapeutics to a “strong sell” rating in a report on Saturday, October 18th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $3.38.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.